ClinicalTrials.gg
CompletedNCT02332590Updated Mar 28, 2022Results posted

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

A Phase 3 interventional study of Sarilumab and Adalimumab in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 86 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
6th of 22
369 · median 88
Started
2015
with 2 others
Phase 3
9 of 22
1 open now
Registered
14th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 14th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate that sarilumab monotherapy was superior to adalimumab monotherapy with respect to signs and symptoms as assessed by disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) in participants with active rheumatoid arthritis (RA) who were either intolerant of, or considered inappropriate candidates for continued treatment with methotrexate (MTX), or after at least 12 weeks of continued treatment with MTX, were determined to be inadequate responders.

Secondary Objectives:

To demonstrate that sarilumab monotherapy was superior to adalimumab monotherapy in participants with active RA who were either intolerant of, or considered inappropriate candidates for continued treatment with MTX, or after at least 12 weeks of continued treatment with MTX, were determined to be inadequate responders, with respect to:

  • Reduction of signs and symptoms of RA.
  • Improvement in quality of life assessed by participant reported outcome questionnaires.

Assessment of the safety and tolerability of sarilumab monotherapy (including immunogenicity) throughout the study.

Read the detailed description

Total study duration was up to 310 weeks: Up to a 4 week screening period, 24 week randomized double-blind treatment phase, 276-week open-label extension, and 6 weeks post-treatment final study visit.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA greater than or equal to (>=)3 months duration.
  • American College of Rheumatology (ACR) Class I-III functional status.
  • Active RA was defined as:

At least 6 of 66 swollen joints and 8 of 68 tender joints, high sensitivity C-reactive protein (hs-CRP) >=8 mg/L or ESR >=28 millimeter per hour (mm/H), and DAS28-ESR greater than (>) 5.1.

  • Participants as per Investigator judgment were either intolerant of, or considered inappropriate candidates for continued treatment with MTX, or after at least 12 weeks of continued treatment with MTX, or inadequate responders treated with an adequate MTX dose for at least 12 weeks.

Exclusion criteria

Exclusion criteria:

  • Age \<18 years or the legal age of consent in the country of the study site, whichever was higher.
  • Current treatment with disease-modifying antirheumatic drug (DMARDs)/ agents including MTX, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 2 weeks prior to the baseline (Randomization Visit) or azathioprine, cyclophosphamide within 12 weeks prior to baseline (Randomization Visit) or leflunomide within 8 weeks prior to the Randomization Visit, or 4 weeks after cholestyramine washout.
  • Treatment with any prior biologic agent, including anti-interleukin 6 (IL-6), IL-6 receptor (IL-6R) antagonists, and prior treatment with a Janus kinase inhibitor.
  • Use of parenteral or intra-articular corticosteroids within 4 weeks prior to screening.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
369 participants (actual)

Study arms

  • Active comparator
    Adalimumab 40 mg/Sarilumab 200 mg

    Adalimumab 40 milligrams (mg) subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during the double-blind (DB) period. The dosing frequency of adalimumab was adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (less than \[\<\] 20% improvement from baseline in tender joint count \[TJC\] and swollen joint count \[SJC\] for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in open label extension (OLE) period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).

    Drug: Adalimumab · Drug: Placebo (for sarilumab)

  • Experimental
    Sarilumab 200 mg/Sarilumab 200 mg

    Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during the DB period. The dosing frequency of placebo for adalimumab was adjusted to 40 mg qw dosing in case of participants with inadequate response (\<20% improvement from baseline in TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in OLE period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).

    Drug: Sarilumab · Drug: Placebo (for adalimumab)

Interventions

  • Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC

    Also known as: SAR153191, REGN88

  • Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC

    Also known as: Humira

  • DrugPlacebo (for sarilumab)

    Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC

  • DrugPlacebo (for adalimumab)

    Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC

06

What researchers measure

Primary outcomes

  1. DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24

    DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR and RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Least square (LS) mean and standard error (SE) at Week 24 were obtained using Mixed-effect model with repeated measures (MMRM) approach.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-ESR <2.6) at Week 24

    DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Participants who discontinued treatment prior to Week 24 were analyzed as non-responders.

    Time frame: Week 24

  2. DB Period: Percentage of Participants Achieving ACR50 Criteria at Week 24

    ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (C-reactive protein \[CRP\] level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\], with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. Participants were analyzed as non-responders from the time they discontinued treatment.

    Time frame: Week 24

  3. DB Period: Percentage of Participants Achieving ACR70 Criteria at Week 24

    ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (CRP level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR70 was defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments. Participants were analyzed as non-responders from the time they discontinued treatment.

    Time frame: Week 24

  4. DB Period: Percentage of Participants Achieving ACR20 Criteria at Week 24

    ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (CRP level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR20 was defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments. Participants were analyzed as non-responders from the time they discontinued treatment.

    Time frame: Week 24

  5. DB Period: Change From Baseline in HAQ-DI at Week 24

    Physical function was assessed by HAQ-DI. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  6. DB Period: Change From Baseline in Short-Form-36 (SF-36) - Physical Component Summary (PCS) Score at Week 24

    SF-36 is a generic 36-item questionnaire consisting of 8 sub-scales, measures health-related quality of life (HRQL) in the last 4 weeks covering 2 summary measures: PCS and mental component summary (MCS). PCS with 4 sub-scales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 sub-scales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a sub-scale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Both PCS and MCS range from 0-100 with higher scores indicating better physical and mental health. LS mean and SE at Week 24 by MMRM approach.

    Time frame: Baseline, Week 24

  7. DB Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24

    The FACIT-F is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranged from 0 to 52, where higher score corresponds to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 24 by MMRM approach.

    Time frame: Baseline, Week 24

  8. DB Period: Change From Baseline in SF-36 - Mental Health Component Summary Score at Week 24

    SF-36 is a generic 36-item questionnaire consisting of 8 sub-scales, measures HRQL in the last 4 weeks covering 2 summary measures: PCS and MCS. PCS with 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Both PCS and MCS range from 0-100 with higher scores indicating better physical and mental health. LS mean and SE at Week 24 by MMRM approach.

    Time frame: Baseline, Week 24

  9. DB Period: Change From Baseline in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP Score) at Week 24

    DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28-CRP score provides a number indicating the current disease activity of the RA. DAS28-CRP total score ranges from 2-10. A DAS28-CRP score above 5.1 means high disease activity, whereas a DAS28-CRP score below 3.2 indicates low disease activity and a DAS28-CRP score below 2.6 means disease remission. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  10. DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP <2.6) at Week 24

    DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by hs-CRP in mg/L. The DAS28-CRP score provides a number indicating the current disease activity of the RA. DAS28-CRP total score ranges from 2-10. A DAS28-CRP score above 5.1 means high disease activity, whereas a DAS28-CRP score below 3.2 indicates low disease activity and a DAS28-CRP score below 2.6 means disease remission. Participants were analyzed as non-responders from the time they discontinued treatment.

    Time frame: Week 24

  11. DB Period: Percentage of Participants Achieving Low Disease Activity (DAS28-ESR < 3.2) at Week 24

    DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Participants were analyzed as non-responders from the time they discontinued treatment.

    Time frame: Week 24

  12. DB Period: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Remission (CDAI ≤2.8) at Week 24

    CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global assessment of disease activity (in cm), and physician's global assessment of disease activity (in cm). Total score ranges from 0 to 76 with a lower score indicating less disease activity. Participants were analyzed as non-responders from the time they discontinued treatment.

    Time frame: Week 24

  13. DB Period: Change From Baseline in CDAI at Week 24

    CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global assessment of disease activity (in cm), and physician's global assessment of disease activity (VAS in cm). Total score ranges from 0 to 76 with a lower score indicating less disease activity. A negative change in CDAI score indicates an improvement in disease activity and a positive change in score indicates a worsening of disease activity. LS means and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  14. DB Period: Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) Scores at Week 24

    EQ-5D-3L is a standardized, generic measure of health outcome. EQ-5D was designed for self-completion by participants. EQ-5D was specifically included to address concerns regarding the health economic impact of RA. EQ-5D-3L comprises of 5 questions on mobility, self-care, pain/discomfort, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems). The 5-dimensional 3-level systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-3L-VAS records the participant's self-rated health on a vertical VAS that allows the participants to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  15. DB Period: Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) at Week 24

    RAID is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well-being, quality of sleep, and coping. The RAID is calculated based on 7 numerical rating scales (NRS) questions. Each NRS is assessed as a number between 0 and 10 that corresponds to the 7 domains. The values for each of these domains are weighed by participant assessment of relative importance and combined in a single score with a total score range of 0 (not affected, very good) to 10 (most affected). LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  16. DB Period: Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to Arthritis

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  17. DB Period: Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to Arthritis

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by \>= 50% in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  18. DB Period: Change From Baseline in WPS-RA at Week 24: Arthritis Interference With Work Productivity

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  19. DB Period: Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to Arthritis

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  20. DB Period: Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by >= 50% Due to Arthritis

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by \>= 50% in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  21. DB Period: Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to Arthritis

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  22. DB Period: Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to Arthritis

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  23. DB Period: Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  24. DB Period: Change From Baseline in Morning Stiffness VAS at Week 24

    RA is associated with stiffness of joints, especially in the morning after prolonged stationery state. The degree of stiffness can be an indicator of disease severity. The severity of morning stiffness was assessed on a VAS scale from 0 mm (no problem) to 100 mm (major problem). LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  25. DB Period: Change From Baseline in Individual ACR Component - TJC and SJC at Week 24

    ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). 68 joints were assessed for tenderness (TJC scoring 0-68) and 66 joints for swelling (SJC scoring 0-66). The 66 SJC evaluated the following joints: temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal, interphalangeal of thumb, distal interphalangeal, proximal interphalangeal, knee, ankle mortise, ankle tarsus, metatarsophalangeal, interphalangeal of great toe, and proximal/distal interphalangeal of the toes. The TJC examined hip joints, in addition to the joints assessed for SJC. Increase in number of tender joints/swollen joints indicated severity. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  26. DB Period: Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 24

    ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). Physician global VAS \& participant global VAS was done on 100 mm horizontal anchored VAS, ranging from 0 "no arthritis activity" to 100 "maximal arthritis activity" and Pain VAS on 100 mm VAS, ranging from 0 "no pain" to 100 "worst pain". LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  27. DB Period: Change From Baseline in Individual ACR Component - CRP Level at Week 24

    ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). An elevated CRP level is considered a non-specific "marker" for RA. A decrease indicates improvement. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  28. DB Period: Change From Baseline in Individual ACR Component- ESR Level at Week 24

    ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). The ESR is a blood test that can reveal inflammatory activity. Inflammation can cause the cells to clump together. The farther the red blood cells have descended, the greater the inflammatory response. LS mean and SE at Week 24 were obtained using MMRM approach.

    Time frame: Baseline, Week 24

  29. DB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Adverse event (AE) was defined as any untoward medical occurrence in participant who received investigational medicinal product (IMP) and did not necessarily had to have causal relationship with treatment. All reported AEs are TEAEs developed/worsened during 'on treatment period' (time from first dose of study drug up to day before first dose of open-label treatment for participants who completed 24-week randomized//DB treatment). SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event.

    Time frame: From Week 0 to Week 24

  30. OLE Period: Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events

    AE was defined as any untoward medical occurrence in participant who received IMP and did not necessarily had to have causal relationship with treatment. All reported AEs are TEAEs developed/worsened during 'on treatment period' (from end of week 24 \[Baseline of OLE Period\] up to last dose in OLE period + 6 weeks \[follow-up\], regardless of unplanned intermittent discontinuations). SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to last dose in OLE + 6 weeks of follow up (i.e. up to Week 306)

  31. DB Period: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) - Hematological Parameters

    Criteria for potentially clinically significant laboratory abnormalities included: * Hemoglobin (Hb): less than or equal to (\<=) 115 grams per liter (g/L) (Male), \<= 95 g/L (Female); greater than or equal to (\>=) 185 g/L (18.5 g/dL) (Male), \>= 165 g/L (16.5 g/dL) (Female); Decrease From Baseline (DFB) = 20 g/L (2 g/dL). * Hematocrit: \<= 0.37 volume/volume (v/v) (Male); \<= 0.32 v/v (F); \>= 0.55 v/v (Male); \>= 0.5 v/v (Female). * Red Blood Cells (RBCs): \>=6 Tera/ liter (L). * Platelets: \< 50 Giga/L, 50 - 100 Giga/L, \>= 700 Giga/L. * White blood cells (WBC): \< 3.0 Giga/L (Non-Black); \< 2.0 Giga/L (Black), \>= 16.0 Giga/L. * Neutrophils: \< 1.0 Giga/L, \< 1.5 Giga/L (Non-Black); \< 1.0 Giga/L (Black). * Lymphocytes: \< 0.5 Giga/L, \>= 0.5 Giga/L - lower limit of normal (LLN), \> 4.0 Giga/L. * Monocytes: \> 0.7 Giga/L. * Basophils: \> 0.1 Giga/L. * Eosinophils: \> 0.5 Giga/L or \> upper limit of normal (ULN) (if ULN \>= 0.5 Giga/L).

    Time frame: From Week 0 to Week 24

  32. OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Hematological Parameters

    Criteria for potentially clinically significant laboratory abnormalities included: * Hb: \<=115 g/L (Male), \<= 95 g/L (Female); \>=185 g/L (18.5 g/dL) (Male), \>= 165 g/L (16.5 g/dL) (Female); DFB \>= 20 g/L (2 g/dL). * Hematocrit: \<= 0.37 v/v (Male); \<= 0.32 v/v (Female); \>= 0.55 v/v (Male); \>= 0.5 v/v (Female). * RBCs: \>=6 Tera/ L. * Platelets: \< 50 Giga/L, \>=50 - 100 Giga/L, \>= 700 Giga/L. * WBC: \< 3.0 Giga/L (Non-Black); \< 2.0 Giga/L (Black), \>= 16.0 Giga/L. * Neutrophils: \< 1.0 Giga/L, \< 1.5 Giga/L (Non-Black); \< 1.0 Giga/L (Black). * Lymphocytes: \< 0.5 Giga/L, \>= 0.5 Giga/L - LLN, \> 4.0 Giga/L. * Monocytes: \> 0.7 Giga/L. * Basophils: \> 0.1 Giga/L. * Eosinophils: \> 0.5 Giga/L or \> ULN (if ULN \>= 0.5 Giga/L).

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  33. DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests

    Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Alkaline phosphatase: \>1.5 ULN. * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN. * Conjugated bilirubin (CBILI): \>1.5 ULN. * Unconjugated bilirubin: \>1.5 ULN, \>2 ULN. * ALT \>3 ULN and TBILI \>2 ULN. * CBILI \>35% TBILI and TBILI \>1.5 ULN. * Albumin: \<=25 g/L.

    Time frame: From Week 0 to Week 24

  34. OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests

    Criteria for potentially clinically significant abnormalities: * ALT: \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * AST: \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Alkaline phosphatase: \>1.5 ULN. * TBILI: \>1.5 ULN; \>2 ULN. * CBILI: \>1.5 ULN. * Unconjugated bilirubin: \>1.5 ULN, \>2 ULN. * ALT \>3 ULN and TBILI \>2 ULN. * CBILI \>35% TBILI and TBILI \>1.5 ULN. * Albumin: \<=25 g/L.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  35. DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters

    Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 millimole/liter (mmol/L) and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]). * Hemoglobin A1c (HbA1c): \>8%. * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L. * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L. * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L.

    Time frame: From Week 0 to Week 24

  36. OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters

    Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfas) or \>=7 mmol/L (fas). * HbA1c: \>8%. * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L. * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L. * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  37. DB Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein (HDL)

    Number of participants with different post-baseline status of HDL: \< 40 mg/dL, 40 - \< 60 mg/dL, \>= 60 mg/dL, is reported here.

    Time frame: From Week 0 to Week 24

  38. OLE Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein

    Number of participants with different post-baseline status of HDL: \< 40 mg/dL, 40 - \< 60 mg/dL, \>=60 mg/dL, is reported here.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  39. DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function

    Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline. * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min. * Blood urea nitrogen: \>=17 mmol/L. * Uric acid: \<120 micromol/L; \>408 micromol/L.

    Time frame: From Week 0 to Week 24

  40. OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function

    Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline. * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min. * Blood urea nitrogen: \>=17 mmol/L. * Uric acid: \<120 micromol/L; \>408 micromol/L.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  41. DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis

    Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0.

    Time frame: From Week 0 to Week 24

  42. OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis

    Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  43. DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes

    Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L. * Potassium: \<3 mmol/L; \>=5.5 mmol/L. * Chloride: \<80 mmol/L; \>115 mmol/L.

    Time frame: From Week 0 to Week 24

  44. OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes

    Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L. * Potassium: \<3 mmol/L; \>=5.5 mmol/L. * Chloride: \<80 mmol/L; \>115 mmol/L.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  45. DB Period: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

    Criteria for potentially clinically significant ECG abnormalities: * Heart rate (HR): \<50 beats per minute (bpm); \<50 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<30 bpm; \<30 bpm and DFB \>=20 bpm; \>90 bpm; \>=90 bpm and increase from baseline (IFB) \>=20 bpm; \>100 bpm; \>=100 bpm and IFB \>=20 bpm; \>120 bpm; \>=120 bpm and IFB \>=20 bpm. * PR Interval: \>200 millisecond (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25%. * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25%. * QT Interval: \>500 ms. * QTc Bazett (QTc B): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms. * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms.

    Time frame: From Week 0 to Week 24

  46. OLE Period: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities

    Criteria for potentially clinically significant ECG abnormalities: * HR: \<50 bpm; \<50 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<30 bpm; \<30 bpm and DFB \>=20 bpm; \>90 bpm; \>=90 bpm and IFB \>=20 bpm; \>100 bpm; \>=100 bpm and IFB \>=20 bpm; \>120 bpm; \>=120 bpm and IFB \>=20 bpm. * PR Interval: \>200 ms; \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25%. * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25%. * QT Interval: \>500 ms. * QTc B: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms. * QTc F: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  47. DB Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

    Criteria for potentially clinically significant vital sign abnormalities: Systolic blood pressure (SBP) supine: \<=95 mmHg and DFB\>=20 mmHg; \>=160 mmHg and IFB \>=20 mmHg. Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg. SBP (Orthostatic): \<=-20 mmHg. DBP (Orthostatic): \<=-10 mmHg. HR supine: \<=50 bpm and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm. Weight: \>=5% DFB; \>=5% IFB.

    Time frame: From Week 0 to Week 24

  48. OLE Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

    Criteria for potentially clinically significant vital sign abnormalities: SBP supine: \<=95 mmHg and DFB \>=20 mmHg; \>=160 mmHg and IFB \>=20 mmHg. DBP supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg. SBP (Orthostatic): \<=-20 mmHg. DBP (Orthostatic): \<=-10 mmHg. HR supine: \<=50 bpm and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm. Weight: \>=5% DFB; \>=5% IFB.

    Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300

  49. DB Period: Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody (ADA) Response

    Anti-drug antibody response was categorized as: Treatment emergent and Treatment-boosted. Treatment emergent ADAs was defined as a participant with no positive assay response at baseline but with a positive assay response during the TEAE period. Treatment boosted ADAs: defined as participants with a positive ADA assay response at baseline and with at least a 4-fold increase in titer compared to baseline during the TEAE period. TEAE period: time from first dose of study drug up to day before first dose of open-label treatment for participants who completed 24-week randomized/DB treatment.

    Time frame: From Week 0 to Week 24

  50. Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody Response During Entire Treatment-emergent Adverse Event Period

    Anti-drug antibody response was categorized as: Treatment emergent and Treatment-boosted. Treatment emergent ADAs was defined as a participant with no positive assay response at baseline but with a positive assay response during the entire TEAE period. Treatment boosted ADAs: defined as participants with a positive ADA assay response at baseline and with at least a 4-fold increase in titer compared to baseline during the entire TEAE period. Entire TEAE period: last OLE dose - first DB dose date + 6 weeks (follow-up), regardless of unplanned intermittent discontinuations.

    Time frame: From Week 0 up to last dose in OLE + 6 weeks of follow-up (i.e. up to Week 306)

  51. DB Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab

    Data for this outcome measure was not planned to be collected and analyzed for "Adalimumab 40 mg/Sarilumab 200 mg" arm.

    Time frame: Pre-dose at Week 0 (Baseline), 2, 4, 12, 16, 20, and 24

  52. OLE Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab

    Time frame: Pre-dose at Week 24 (Baseline of OLE period), 36, 48, 60, 84, 108, 132, 156, 180, 204, 228, 252, 276, 300 and 306

07

Results

Posted Jul 25, 2017

Participant flow

The study was conducted at 86 centers in 15 countries. A total of 540 participants were involved in the study from 28 January 2015 to 29-December-2020, of whom 369 participants were randomized and 171 were screen failures. Screen failures were mainly due to exclusion criteria met and inclusion criteria not met.

DB Period (up to 24 Weeks)
Participant flow — DB Period (up to 24 Weeks)
MilestoneAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Started185184
Treated184184
Completed156165
Not completed2919
Withdrew: Adverse event1511
Withdrew: Lack of efficacy42
Withdrew: Poor compliance to protocol31
Withdrew: Randomized but not treated10
Withdrew: Other than specified above65
OLE Period (Week 24 up to Week 300)
Participant flow — OLE Period (Week 24 up to Week 300)
MilestoneAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Started155165
Completed108120
Not completed4745
Withdrew: Adverse event2023
Withdrew: Lack of efficacy26
Withdrew: Poor compliance to protocol51
Withdrew: Other unspecified2015

Outcome measures

PrimaryDB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24

DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR and RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Least square (LS) mean and standard error (SE) at Week 24 were obtained using Mixed-effect model with repeated measures (MMRM) approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24-2.20 ± 0.106-3.28 ± 0.105
Statistical analysis
  • Adalimumab 40 mg/Sarilumab 200 mg vs Sarilumab 200 mg/Sarilumab 200 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -1.077 · 95% CI -1.361 to -0.793Sarilumab 200 mg vs. Adalimumab 40 mg
SecondaryDB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-ESR <2.6) at Week 24

DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Participants who discontinued treatment prior to Week 24 were analyzed as non-responders.

Time frame:
Week 24
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-ESR <2.6) at Week 24
percentage of participantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-ESR <2.6) at Week 247.026.6
Statistical analysis
  • Adalimumab 40 mg/Sarilumab 200 mg vs Sarilumab 200 mg/Sarilumab 200 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 4.879 · 95% CI 2.536 to 9.389Sarilumab 200 mg vs. Adalimumab 40 mg
SecondaryDB Period: Percentage of Participants Achieving ACR50 Criteria at Week 24

ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (C-reactive protein \[CRP\] level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\], with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. Participants were analyzed as non-responders from the time they discontinued treatment.

Time frame:
Week 24
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Achieving ACR50 Criteria at Week 24
percentage of participantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Percentage of Participants Achieving ACR50 Criteria at Week 2429.745.7
Statistical analysis
  • Adalimumab 40 mg/Sarilumab 200 mg vs Sarilumab 200 mg/Sarilumab 200 mg · Cochran-Mantel-Haenszel · p = 0.0017 (Threshold for significance at 0.05 level.) · Odds ratio (or): 1.976 · 95% CI 1.289 to 3.028Sarilumab 200 mg vs. Adalimumab 40 mg
SecondaryDB Period: Percentage of Participants Achieving ACR70 Criteria at Week 24

ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (CRP level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR70 was defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments. Participants were analyzed as non-responders from the time they discontinued treatment.

Time frame:
Week 24
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Achieving ACR70 Criteria at Week 24
percentage of participantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Percentage of Participants Achieving ACR70 Criteria at Week 2411.923.4
Statistical analysis
  • Adalimumab 40 mg/Sarilumab 200 mg vs Sarilumab 200 mg/Sarilumab 200 mg · Cochran-Mantel-Haenszel · p = 0.0036 (Threshold for significance at 0.05 level.) · Odds ratio (or): 2.286 · 95% CI 1.300 to 4.020Sarilumab 200 mg vs. Adalimumab 40 mg
SecondaryDB Period: Percentage of Participants Achieving ACR20 Criteria at Week 24

ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (CRP level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR20 was defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments. Participants were analyzed as non-responders from the time they discontinued treatment.

Time frame:
Week 24
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Achieving ACR20 Criteria at Week 24
percentage of participantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Percentage of Participants Achieving ACR20 Criteria at Week 2458.471.7
Statistical analysis
  • Adalimumab 40 mg/Sarilumab 200 mg vs Sarilumab 200 mg/Sarilumab 200 mg · Cochran-Mantel-Haenszel · p = 0.0074 (Threshold for significance 0.05 level.) · Odds ratio (or): 1.800 · 95% CI 1.168 to 2.773Sarilumab 200 mg vs. Adalimumab 40 mg
SecondaryDB Period: Change From Baseline in HAQ-DI at Week 24

Physical function was assessed by HAQ-DI. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in HAQ-DI at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in HAQ-DI at Week 24-0.43 ± 0.045-0.61 ± 0.045
Statistical analysis
  • Adalimumab 40 mg/Sarilumab 200 mg vs Sarilumab 200 mg/Sarilumab 200 mg · Mixed Models Analysis · p = 0.0037 (Threshold for significance at 0.05 level.) · Ls mean difference: -0.182 · 95% CI -0.305 to -0.059Sarilumab 200 mg vs. Adalimumab 40 mg
SecondaryDB Period: Change From Baseline in Short-Form-36 (SF-36) - Physical Component Summary (PCS) Score at Week 24

SF-36 is a generic 36-item questionnaire consisting of 8 sub-scales, measures health-related quality of life (HRQL) in the last 4 weeks covering 2 summary measures: PCS and mental component summary (MCS). PCS with 4 sub-scales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 sub-scales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a sub-scale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Both PCS and MCS range from 0-100 with higher scores indicating better physical and mental health. LS mean and SE at Week 24 by MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in Short-Form-36 (SF-36) - Physical Component Summary (PCS) Score at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Short-Form-36 (SF-36) - Physical Component Summary (PCS) Score at Week 246.09 ± 0.5558.74 ± 0.555
Statistical analysis
  • Adalimumab 40 mg/Sarilumab 200 mg vs Sarilumab 200 mg/Sarilumab 200 mg · Mixed Models Analysis · p = 0.0006 (Threshold for significance at 0.05 level.) · Ls mean difference: 2.650 · 95% CI 1.147 to 4.153Sarilumab 200 mg vs. Adalimumab 40 mg
SecondaryDB Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24

The FACIT-F is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranged from 0 to 52, where higher score corresponds to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 24 by MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 248.41 ± 0.70910.18 ± 0.701
Statistical analysis
  • Adalimumab 40 mg/Sarilumab 200 mg vs Sarilumab 200 mg/Sarilumab 200 mg · Mixed Models Analysis · p = 0.0689 (Threshold for significance at 0.05 level.) · Ls mean difference: 1.768 · 95% CI -0.137 to 3.674Sarilumab 200 mg vs. Adalimumab 40 mg
SecondaryDB Period: Change From Baseline in SF-36 - Mental Health Component Summary Score at Week 24

SF-36 is a generic 36-item questionnaire consisting of 8 sub-scales, measures HRQL in the last 4 weeks covering 2 summary measures: PCS and MCS. PCS with 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Both PCS and MCS range from 0-100 with higher scores indicating better physical and mental health. LS mean and SE at Week 24 by MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in SF-36 - Mental Health Component Summary Score at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in SF-36 - Mental Health Component Summary Score at Week 246.83 ± 0.7747.86 ± 0.773
SecondaryDB Period: Change From Baseline in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP Score) at Week 24

DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28-CRP score provides a number indicating the current disease activity of the RA. DAS28-CRP total score ranges from 2-10. A DAS28-CRP score above 5.1 means high disease activity, whereas a DAS28-CRP score below 3.2 indicates low disease activity and a DAS28-CRP score below 2.6 means disease remission. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP Score) at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP Score) at Week 24-1.97 ± 0.094-2.86 ± 0.093
SecondaryDB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP <2.6) at Week 24

DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by hs-CRP in mg/L. The DAS28-CRP score provides a number indicating the current disease activity of the RA. DAS28-CRP total score ranges from 2-10. A DAS28-CRP score above 5.1 means high disease activity, whereas a DAS28-CRP score below 3.2 indicates low disease activity and a DAS28-CRP score below 2.6 means disease remission. Participants were analyzed as non-responders from the time they discontinued treatment.

Time frame:
Week 24
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP <2.6) at Week 24
percentage of participantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP <2.6) at Week 2413.534.2
SecondaryDB Period: Percentage of Participants Achieving Low Disease Activity (DAS28-ESR < 3.2) at Week 24

DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Participants were analyzed as non-responders from the time they discontinued treatment.

Time frame:
Week 24
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Achieving Low Disease Activity (DAS28-ESR < 3.2) at Week 24
percentage of participantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Percentage of Participants Achieving Low Disease Activity (DAS28-ESR < 3.2) at Week 2414.142.9
SecondaryDB Period: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Remission (CDAI ≤2.8) at Week 24

CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global assessment of disease activity (in cm), and physician's global assessment of disease activity (in cm). Total score ranges from 0 to 76 with a lower score indicating less disease activity. Participants were analyzed as non-responders from the time they discontinued treatment.

Time frame:
Week 24
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Remission (CDAI ≤2.8) at Week 24
percentage of participantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Remission (CDAI ≤2.8) at Week 242.77.1
SecondaryDB Period: Change From Baseline in CDAI at Week 24

CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global assessment of disease activity (in cm), and physician's global assessment of disease activity (VAS in cm). Total score ranges from 0 to 76 with a lower score indicating less disease activity. A negative change in CDAI score indicates an improvement in disease activity and a positive change in score indicates a worsening of disease activity. LS means and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in CDAI at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in CDAI at Week 24-25.20 ± 0.842-28.94 ± 0.834
SecondaryDB Period: Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) Scores at Week 24

EQ-5D-3L is a standardized, generic measure of health outcome. EQ-5D was designed for self-completion by participants. EQ-5D was specifically included to address concerns regarding the health economic impact of RA. EQ-5D-3L comprises of 5 questions on mobility, self-care, pain/discomfort, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems). The 5-dimensional 3-level systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-3L-VAS records the participant's self-rated health on a vertical VAS that allows the participants to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) Scores at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
EQ-5D Single index utility score0.26 ± 0.0190.32 ± 0.019
EQ-5D VAS19.94 ± 1.72024.22 ± 1.686
SecondaryDB Period: Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) at Week 24

RAID is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well-being, quality of sleep, and coping. The RAID is calculated based on 7 numerical rating scales (NRS) questions. Each NRS is assessed as a number between 0 and 10 that corresponds to the 7 domains. The values for each of these domains are weighed by participant assessment of relative importance and combined in a single score with a total score range of 0 (not affected, very good) to 10 (most affected). LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) at Week 24
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) at Week 24-2.30 ± 0.168-3.08 ± 0.168
SecondaryDB Period: Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to Arthritis

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · days
DB Period: Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to Arthritis
daysAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to Arthritis0.05 ± 0.611-0.28 ± 0.547
SecondaryDB Period: Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to Arthritis

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by \>= 50% in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · days
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to Arthritis
daysAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to Arthritis-3.50 ± 0.525-3.74 ± 0.456
SecondaryDB Period: Change From Baseline in WPS-RA at Week 24: Arthritis Interference With Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in WPS-RA at Week 24: Arthritis Interference With Work Productivity
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in WPS-RA at Week 24: Arthritis Interference With Work Productivity-2.510 ± 0.3470-2.919 ± 0.3073
SecondaryDB Period: Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to Arthritis

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · days
DB Period: Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to Arthritis
daysAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to Arthritis-4.22 ± 0.405-5.49 ± 0.400
SecondaryDB Period: Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by >= 50% Due to Arthritis

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by \>= 50% in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · days
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by >= 50% Due to Arthritis
daysAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by >= 50% Due to Arthritis-4.87 ± 0.451-6.70 ± 0.445
SecondaryDB Period: Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to Arthritis

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · days
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to Arthritis
daysAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to Arthritis-3.33 ± 0.376-4.14 ± 0.371
SecondaryDB Period: Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to Arthritis

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · days
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to Arthritis
daysAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to Arthritis-2.57 ± 0.401-3.43 ± 0.398
SecondaryDB Period: Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity
units on a scaleAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity-2.605 ± 0.2110-3.276 ± 0.2099
SecondaryDB Period: Change From Baseline in Morning Stiffness VAS at Week 24

RA is associated with stiffness of joints, especially in the morning after prolonged stationery state. The degree of stiffness can be an indicator of disease severity. The severity of morning stiffness was assessed on a VAS scale from 0 mm (no problem) to 100 mm (major problem). LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mm
DB Period: Change From Baseline in Morning Stiffness VAS at Week 24
mmAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Morning Stiffness VAS at Week 24-29.29 ± 1.970-35.08 ± 1.947
SecondaryDB Period: Change From Baseline in Individual ACR Component - TJC and SJC at Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). 68 joints were assessed for tenderness (TJC scoring 0-68) and 66 joints for swelling (SJC scoring 0-66). The 66 SJC evaluated the following joints: temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal, interphalangeal of thumb, distal interphalangeal, proximal interphalangeal, knee, ankle mortise, ankle tarsus, metatarsophalangeal, interphalangeal of great toe, and proximal/distal interphalangeal of the toes. The TJC examined hip joints, in addition to the joints assessed for SJC. Increase in number of tender joints/swollen joints indicated severity. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · joints
DB Period: Change From Baseline in Individual ACR Component - TJC and SJC at Week 24
jointsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
TJC-16.45 ± 0.781-18.23 ± 0.772
SJC-12.20 ± 0.450-13.44 ± 0.444
SecondaryDB Period: Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). Physician global VAS \& participant global VAS was done on 100 mm horizontal anchored VAS, ranging from 0 "no arthritis activity" to 100 "maximal arthritis activity" and Pain VAS on 100 mm VAS, ranging from 0 "no pain" to 100 "worst pain". LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mm
DB Period: Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 24
mmAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Physician global VAS-37.80 ± 1.431-45.33 ± 1.414
Participant global VAS-24.82 ± 1.752-33.30 ± 1.731
Pain VAS-27.41 ± 1.802-36.19 ± 1.776
SecondaryDB Period: Change From Baseline in Individual ACR Component - CRP Level at Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). An elevated CRP level is considered a non-specific "marker" for RA. A decrease indicates improvement. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mg/L
DB Period: Change From Baseline in Individual ACR Component - CRP Level at Week 24
mg/LAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Individual ACR Component - CRP Level at Week 24-2.91 ± 1.461-17.01 ± 1.431
SecondaryDB Period: Change From Baseline in Individual ACR Component- ESR Level at Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). The ESR is a blood test that can reveal inflammatory activity. Inflammation can cause the cells to clump together. The farther the red blood cells have descended, the greater the inflammatory response. LS mean and SE at Week 24 were obtained using MMRM approach.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mm/hr
DB Period: Change From Baseline in Individual ACR Component- ESR Level at Week 24
mm/hrAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
DB Period: Change From Baseline in Individual ACR Component- ESR Level at Week 24-12.74 ± 1.398-32.11 ± 1.388
SecondaryDB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Adverse event (AE) was defined as any untoward medical occurrence in participant who received investigational medicinal product (IMP) and did not necessarily had to have causal relationship with treatment. All reported AEs are TEAEs developed/worsened during 'on treatment period' (time from first dose of study drug up to day before first dose of open-label treatment for participants who completed 24-week randomized//DB treatment). SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
TEAEs117118
SAEs139
SecondaryOLE Period: Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events

AE was defined as any untoward medical occurrence in participant who received IMP and did not necessarily had to have causal relationship with treatment. All reported AEs are TEAEs developed/worsened during 'on treatment period' (from end of week 24 \[Baseline of OLE Period\] up to last dose in OLE period + 6 weeks \[follow-up\], regardless of unplanned intermittent discontinuations). SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to last dose in OLE + 6 weeks of follow up (i.e. up to Week 306)
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
TEAE135143
SAE3125
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) - Hematological Parameters

Criteria for potentially clinically significant laboratory abnormalities included: * Hemoglobin (Hb): less than or equal to (\<=) 115 grams per liter (g/L) (Male), \<= 95 g/L (Female); greater than or equal to (\>=) 185 g/L (18.5 g/dL) (Male), \>= 165 g/L (16.5 g/dL) (Female); Decrease From Baseline (DFB) = 20 g/L (2 g/dL). * Hematocrit: \<= 0.37 volume/volume (v/v) (Male); \<= 0.32 v/v (F); \>= 0.55 v/v (Male); \>= 0.5 v/v (Female). * Red Blood Cells (RBCs): \>=6 Tera/ liter (L). * Platelets: \< 50 Giga/L, 50 - 100 Giga/L, \>= 700 Giga/L. * White blood cells (WBC): \< 3.0 Giga/L (Non-Black); \< 2.0 Giga/L (Black), \>= 16.0 Giga/L. * Neutrophils: \< 1.0 Giga/L, \< 1.5 Giga/L (Non-Black); \< 1.0 Giga/L (Black). * Lymphocytes: \< 0.5 Giga/L, \>= 0.5 Giga/L - lower limit of normal (LLN), \> 4.0 Giga/L. * Monocytes: \> 0.7 Giga/L. * Basophils: \> 0.1 Giga/L. * Eosinophils: \> 0.5 Giga/L or \> upper limit of normal (ULN) (if ULN \>= 0.5 Giga/L).

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) - Hematological Parameters
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Hb:<=115 g/L, <=95 g/L127
Hb: >=185 g/L, >=165 g/L01
Hb: DFB >=20 g/L55
Hematocrit: <= 0.37 v/v; <=0.32 v/v2110
Hematocrit: >=0.55 v/v; >=0.5 v/v13
RBCs: >=6 Tera/L01
Platelets: < 50 Giga/L01
Platelets: 50 - 100 Giga/L00
Platelets: >= 700 Giga/L10
WBC: < 3.0 Giga/L (Non-Black); < 2.0 Giga/L (Black)132
WBC: >= 16.0 Giga/L85
Neutrophils: < 1.0 Giga/L219
Neutrophils: < 1.5 Giga/L (Non-Black); < 1.0 Giga/L (Black)750
Lymphocytes: < 0.5 Giga/L22
Lymphocytes: >= 0.5 Giga/L - LLN821
Lymphocytes: > 4.0 Giga/L176
Monocytes: > 0.7 Giga/L4638
Basophils: > 0.1 Giga/L5337
Eosinophils: > 0.5 Giga/L or > ULN (if ULN >= 0.5 Giga/L)49
SecondaryOLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Hematological Parameters

Criteria for potentially clinically significant laboratory abnormalities included: * Hb: \<=115 g/L (Male), \<= 95 g/L (Female); \>=185 g/L (18.5 g/dL) (Male), \>= 165 g/L (16.5 g/dL) (Female); DFB \>= 20 g/L (2 g/dL). * Hematocrit: \<= 0.37 v/v (Male); \<= 0.32 v/v (Female); \>= 0.55 v/v (Male); \>= 0.5 v/v (Female). * RBCs: \>=6 Tera/ L. * Platelets: \< 50 Giga/L, \>=50 - 100 Giga/L, \>= 700 Giga/L. * WBC: \< 3.0 Giga/L (Non-Black); \< 2.0 Giga/L (Black), \>= 16.0 Giga/L. * Neutrophils: \< 1.0 Giga/L, \< 1.5 Giga/L (Non-Black); \< 1.0 Giga/L (Black). * Lymphocytes: \< 0.5 Giga/L, \>= 0.5 Giga/L - LLN, \> 4.0 Giga/L. * Monocytes: \> 0.7 Giga/L. * Basophils: \> 0.1 Giga/L. * Eosinophils: \> 0.5 Giga/L or \> ULN (if ULN \>= 0.5 Giga/L).

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Hematological Parameters
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Hb:<=115 g/L, <=95 g/L85
Hb: >=185 g/L, >=165 g/L33
Hb: DFB >=20 g/L1313
Hematocrit: <= 0.37 v/v; <=0.32 v/v1214
Hematocrit: >=0.55 v/v; >=0.5 v/v58
RBCs: >=6 Tera/L32
Platelets: < 50 Giga/L00
Platelets: >=50 - 100 Giga/L44
Platelets: >= 700 Giga/L21
WBC: < 3.0 Giga/L (Non-Black); < 2.0 Giga/L (Black)3446
WBC: >= 16.0 Giga/L117
Neutrophils: < 1.0 Giga/L2425
Neutrophils: < 1.5 Giga/L (Non-Black); < 1.0 Giga/L (Black)6269
Lymphocytes: < 0.5 Giga/L23
Lymphocytes: >= 0.5 Giga/L - LLN2842
Lymphocytes: > 4.0 Giga/L157
Monocytes: > 0.7 Giga/L4843
Basophils: > 0.1 Giga/L7870
Eosinophils: > 0.5 Giga/L or > ULN (if ULN >= 0.5 Giga/L)1114
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests

Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Alkaline phosphatase: \>1.5 ULN. * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN. * Conjugated bilirubin (CBILI): \>1.5 ULN. * Unconjugated bilirubin: \>1.5 ULN, \>2 ULN. * ALT \>3 ULN and TBILI \>2 ULN. * CBILI \>35% TBILI and TBILI \>1.5 ULN. * Albumin: \<=25 g/L.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
ALT >1 ULN and <=1.5 ULN2236
ALT >1.5 ULN and <=3 ULN1726
ALT >3 ULN and <=5 ULN35
ALT >5 ULN and <=10 ULN11
ALT >10 ULN and <=20 ULN10
ALT >20 ULN00
AST >1 ULN and <=1.5 ULN1622
AST >1.5 ULN and <=3 ULN713
AST >3 ULN and <=5 ULN32
AST >5 ULN and <=10 ULN00
AST >10 ULN and <=20 ULN10
AST >20 ULN00
Alkaline Phosphatase >1.5 ULN62
TBILI >1.5 ULN17
TBILI >2 ULN02
CBILI >1.5 ULN00
Unconjugated Bilirubin >1.5 ULN513
Unconjugated Bilirubin >2 ULN17
ALT> 3 ULN and TBILI >2 ULN00
CBILI >35% TBILI and TBILI >1.5 ULN00
Albumin <=25 g/L00
SecondaryOLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests

Criteria for potentially clinically significant abnormalities: * ALT: \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * AST: \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Alkaline phosphatase: \>1.5 ULN. * TBILI: \>1.5 ULN; \>2 ULN. * CBILI: \>1.5 ULN. * Unconjugated bilirubin: \>1.5 ULN, \>2 ULN. * ALT \>3 ULN and TBILI \>2 ULN. * CBILI \>35% TBILI and TBILI \>1.5 ULN. * Albumin: \<=25 g/L.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
ALT >1 ULN and <=1.5 ULN4136
ALT >1.5 ULN and <=3 ULN3134
ALT >3 ULN and <=5 ULN1110
ALT >5 ULN and <=10 ULN16
ALT >10 ULN and <=20 ULN02
ALT >20 ULN11
AST >1 ULN and <=1.5 ULN2539
AST >1.5 ULN and <=3 ULN2317
AST >3 ULN and <=5 ULN27
AST >5 ULN and <=10 ULN22
AST >10 ULN and <=20 ULN00
AST >20 ULN01
Alkaline Phosphatase >1.5 ULN01
TBILI >1.5 ULN116
TBILI >2 ULN31
CBILI >1.5 ULN00
Unconjugated Bilirubin >1.5 ULN2122
Unconjugated Bilirubin >2 ULN1110
ALT> 3 ULN and TBILI >2 ULN10
CBILI >35% TBILI and TBILI >1.5 ULN00
Albumin <=25 g/L00
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters

Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 millimole/liter (mmol/L) and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]). * Hemoglobin A1c (HbA1c): \>8%. * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L. * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L. * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Glucose <=3.9 mmol/L and <LLN108
Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas)1712
HbA1c >8%33
Total Cholesterol >=6.2 mmol/L5288
Total Cholesterol >=7.74 mmol/L1514
LDL Cholesterol >=4.1 mmol/L3559
LDL Cholesterol >=4.9 mmol/L1820
Triglycerides >=4.6 mmol/L48
Triglycerides >=5.6 mmol/L36
SecondaryOLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters

Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfas) or \>=7 mmol/L (fas). * HbA1c: \>8%. * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L. * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L. * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Glucose <=3.9 mmol/L and <LLN56
Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas)2014
HbA1c >8%22
Total Cholesterol >=6.2 mmol/L7769
Total Cholesterol >=7.74 mmol/L2219
LDL Cholesterol >=4.1 mmol/L5748
LDL Cholesterol >=4.9 mmol/L2516
Triglycerides >=4.6 mmol/L136
Triglycerides >=5.6 mmol/L46
SecondaryDB Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein (HDL)

Number of participants with different post-baseline status of HDL: \< 40 mg/dL, 40 - \< 60 mg/dL, \>= 60 mg/dL, is reported here.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein (HDL)
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
HDL: < 40 mg/dL57
HDL: 40 - < 60 mg/dL5745
HDL: >=60 mg/dL119132
SecondaryOLE Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein

Number of participants with different post-baseline status of HDL: \< 40 mg/dL, 40 - \< 60 mg/dL, \>=60 mg/dL, is reported here.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
HDL: < 40 mg/dL75
HDL: 40 - < 60 mg/dL5249
HDL: >=60 mg/dL94111
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function

Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline. * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min. * Blood urea nitrogen: \>=17 mmol/L. * Uric acid: \<120 micromol/L; \>408 micromol/L.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Creatinine >=150 micromol/L (Adults)03
Creatinine >=30% change from baseline1923
Creatinine >=100% change from baseline01
Creatinine Clearance <15 mL/min00
Creatinine clearance >=15 to <30 mL/min01
Creatinine clearance >=30 to <60 mL/min2122
Creatinine clearance >=60 to <90 mL/min7465
Blood Urea Nitrogen >=17 mmol/L02
Uric acid <120 micromol/L43
Uric acid >408 micromol/L2535
SecondaryOLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function

Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline. * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min. * Blood urea nitrogen: \>=17 mmol/L. * Uric acid: \<120 micromol/L; \>408 micromol/L.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Creatinine >=150 micromol/L (Adults)22
Creatinine >=30% change from baseline6362
Creatinine >=100% change from baseline51
Creatinine Clearance <15 mL/min00
Creatinine clearance >=15 to <30 mL/min10
Creatinine clearance >=30 to <60 mL/min3424
Creatinine clearance >=60 to <90 mL/min6681
Blood Urea Nitrogen >=17 mmol/L13
Uric acid <120 micromol/L23
Uric acid >408 micromol/L4443
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis

Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
pH <= 4.600
pH >= 8.000
SecondaryOLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis

Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
pH <= 4.600
pH >= 8.001
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes

Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L. * Potassium: \<3 mmol/L; \>=5.5 mmol/L. * Chloride: \<80 mmol/L; \>115 mmol/L.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Sodium <=129 mmol/L11
Sodium >=160 mmol/L00
Potassium <3 mmol/L30
Potassium >=5.5 mmol/L00
Chloride <80 mmol/L00
Chloride >115 mmol/L01
SecondaryOLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes

Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L. * Potassium: \<3 mmol/L; \>=5.5 mmol/L. * Chloride: \<80 mmol/L; \>115 mmol/L.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Sodium <=129 mmol/L30
Sodium >=160 mmol/L00
Potassium <3 mmol/L22
Potassium >=5.5 mmol/L67
Chloride <80 mmol/L10
Chloride >115 mmol/L00
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

Criteria for potentially clinically significant ECG abnormalities: * Heart rate (HR): \<50 beats per minute (bpm); \<50 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<30 bpm; \<30 bpm and DFB \>=20 bpm; \>90 bpm; \>=90 bpm and increase from baseline (IFB) \>=20 bpm; \>100 bpm; \>=100 bpm and IFB \>=20 bpm; \>120 bpm; \>=120 bpm and IFB \>=20 bpm. * PR Interval: \>200 millisecond (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25%. * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25%. * QT Interval: \>500 ms. * QTc Bazett (QTc B): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms. * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
HR <50 bpm45
HR <50 bpm and DFB >=20 bpm00
HR <40 bpm00
HR <40 bpm and DFB >=20 bpm00
HR <30 bpm00
HR <30 bpm and DFB >=20 bpm00
HR >90 bpm112
HR >=90 bpm and IFB >=20 bpm51
HR >100 bpm21
HR >=100 bpm and IFB >=20 bpm20
HR >120 bpm00
HR >=120 bpm and IFB >=20 bpm00
PR Interval >200 ms115
PR Interval >200 ms and IFB >=25%10
PR Interval >220 ms41
PR Interval >220 ms and IFB >=25%00
PR Interval >240 ms11
PR Interval >240 ms and IFB >=25%00
QRS Interval >110 ms39
QRS Interval >110 ms and IFB >=25%00
QRS Interval >120 ms12
QRS Interval >120 ms and IFB >=25%00
QT Interval >500 ms01
QTc B >450 ms167
QTc B >480 ms20
QTc B >500 ms00
QTc B IFB >30 and <=60 ms115
QTc B IFB >60 ms00
QTc F>450 ms75
QTc F>480 ms00
QTc F>500 ms00
QTc F IFB >30 and <=60 ms93
QTc F IFB >60 ms00
SecondaryOLE Period: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities

Criteria for potentially clinically significant ECG abnormalities: * HR: \<50 bpm; \<50 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<30 bpm; \<30 bpm and DFB \>=20 bpm; \>90 bpm; \>=90 bpm and IFB \>=20 bpm; \>100 bpm; \>=100 bpm and IFB \>=20 bpm; \>120 bpm; \>=120 bpm and IFB \>=20 bpm. * PR Interval: \>200 ms; \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25%. * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25%. * QT Interval: \>500 ms. * QTc B: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms. * QTc F: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
HR <50 bpm1019
HR <50 bpm and DFB >=20 bpm03
HR <40 bpm11
HR <40 bpm and DFB >=20 bpm01
HR <30 bpm00
HR <30 bpm and DFB >=20 bpm00
HR >90 bpm1611
HR >=90 bpm and IFB >=20 bpm76
HR >100 bpm33
HR >=100 bpm and IFB >=20 bpm21
HR >120 bpm00
HR >=120 bpm and IFB >=20 bpm00
PR Interval >200 ms1714
PR Interval >200 ms and IFB >=25%63
PR Interval >220 ms86
PR Interval >220 ms and IFB >=25%43
PR Interval >240 ms22
PR Interval >240 ms and IFB >=25%21
QRS Interval >110 ms818
QRS Interval >110 ms and IFB >=25%21
QRS Interval >120 ms37
QRS Interval >120 ms and IFB >=25%10
QT Interval >500 ms22
QTc B >450 ms3533
QTc B >480 ms330
QTc B >500 ms11
QTc B IFB >30 and <=60 ms1823
QTc B IFB >60 ms32
QTc F>450 ms1616
QTc F>480 ms32
QTc F>500 ms01
QTc F IFB >30 and <=60 ms1919
QTc F IFB >60 ms43
SecondaryDB Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

Criteria for potentially clinically significant vital sign abnormalities: Systolic blood pressure (SBP) supine: \<=95 mmHg and DFB\>=20 mmHg; \>=160 mmHg and IFB \>=20 mmHg. Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg. SBP (Orthostatic): \<=-20 mmHg. DBP (Orthostatic): \<=-10 mmHg. HR supine: \<=50 bpm and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm. Weight: \>=5% DFB; \>=5% IFB.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
SBP (supine) <=95 mmHg and DFB >=20 mmHg43
SBP (supine) >=160 mmHg and IFB >=20 mmHg45
DBP (supine) <=45 mmHg and DFB >=10 mmHg11
DBP (supine) >=110 mmHg and IFB >=10 mmHg11
SBP (orthostatic) <=-20 mmHg1310
DBP (orthostatic) <=-10 mmHg2027
HR (supine) <=50 bpm and DFB >= 20 bpm21
HR (supine) >=120 bpm and IFB >=20 bpm10
Weight >=5% DFB126
Weight >=5% IFB2123
SecondaryOLE Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

Criteria for potentially clinically significant vital sign abnormalities: SBP supine: \<=95 mmHg and DFB \>=20 mmHg; \>=160 mmHg and IFB \>=20 mmHg. DBP supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg. SBP (Orthostatic): \<=-20 mmHg. DBP (Orthostatic): \<=-10 mmHg. HR supine: \<=50 bpm and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm. Weight: \>=5% DFB; \>=5% IFB.

Time frame:
From end of Week 24 (Baseline of OLE Period) up to Week 300
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
SBP (supine) <=95 mmHg and DFB >=20 mmHg39
SBP (supine) >=160 mmHg and IFB >=20 mmHg1011
DBP (supine) <=45 mmHg and DFB >=10 mmHg00
DBP (supine) >=110 mmHg and IFB >=10 mmHg12
SBP (orthostatic) <=-20 mmHg2432
DBP (orthostatic) <=-10 mmHg4146
HR (supine) <=50 bpm and DFB >= 20 bpm30
HR (supine) >=120 bpm and IFB >=20 bpm00
Weight >=5% DFB4451
Weight >=5% IFB8287
SecondaryDB Period: Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody (ADA) Response

Anti-drug antibody response was categorized as: Treatment emergent and Treatment-boosted. Treatment emergent ADAs was defined as a participant with no positive assay response at baseline but with a positive assay response during the TEAE period. Treatment boosted ADAs: defined as participants with a positive ADA assay response at baseline and with at least a 4-fold increase in titer compared to baseline during the TEAE period. TEAE period: time from first dose of study drug up to day before first dose of open-label treatment for participants who completed 24-week randomized/DB treatment.

Time frame:
From Week 0 to Week 24
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody (ADA) Response
ParticipantsSarilumab 200 mg/Sarilumab 200 mg
Treatment-emergent ADA13
Treatment-boosted ADA0
SecondaryNumber of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody Response During Entire Treatment-emergent Adverse Event Period

Anti-drug antibody response was categorized as: Treatment emergent and Treatment-boosted. Treatment emergent ADAs was defined as a participant with no positive assay response at baseline but with a positive assay response during the entire TEAE period. Treatment boosted ADAs: defined as participants with a positive ADA assay response at baseline and with at least a 4-fold increase in titer compared to baseline during the entire TEAE period. Entire TEAE period: last OLE dose - first DB dose date + 6 weeks (follow-up), regardless of unplanned intermittent discontinuations.

Time frame:
From Week 0 up to last dose in OLE + 6 weeks of follow-up (i.e. up to Week 306)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody Response During Entire Treatment-emergent Adverse Event Period
ParticipantsAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Treatment-emergent ADAs1111
Treatment-boosted ADAs00
SecondaryDB Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab

Data for this outcome measure was not planned to be collected and analyzed for "Adalimumab 40 mg/Sarilumab 200 mg" arm.

Time frame:
Pre-dose at Week 0 (Baseline), 2, 4, 12, 16, 20, and 24
Reported as:
Mean · nanograms per milliliter (ng/mL)
DB Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab
nanograms per milliliter (ng/mL)Sarilumab 200 mg/Sarilumab 200 mg
Baseline0.00 ± 0.00
Week 25566.03 ± 4843.57
Week 411209.64 ± 8202.70
Week 1221355.19 ± 14805.63
Week 1623143.39 ± 16508.71
Week 2025252.43 ± 17319.04
Week 2424233.10 ± 17581.72
SecondaryOLE Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab
Time frame:
Pre-dose at Week 24 (Baseline of OLE period), 36, 48, 60, 84, 108, 132, 156, 180, 204, 228, 252, 276, 300 and 306
Reported as:
Mean · ng/mL
OLE Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab
ng/mLAdalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mg
Week 24 (Baseline of OLE period)109.38 ± 1237.4424403.72 ± 17588.31
Week 3618952.69 ± 15125.8626006.07 ± 19194.79
Week 4821911.87 ± 17926.0125571.16 ± 18958.00
Week 6021583.82 ± 17594.8724005.78 ± 18541.46
Week 8423230.92 ± 18274.0923873.23 ± 19794.57
Week 10820405.02 ± 15553.0221023.55 ± 17792.89
Week 13220814.89 ± 17848.7020021.53 ± 18580.91
Week 15623604.11 ± 19660.3122423.29 ± 18757.11
Week 18018611.01 ± 16417.4621856.85 ± 18612.43
Week 20417982.66 ± 16640.6118244.96 ± 16383.47
Week 22819451.40 ± 17694.0918315.19 ± 17525.62
Week 25219663.10 ± 16020.1119224.47 ± 16964.41
Week 27619071.00 ± 18425.1317014.75 ± 16207.18
Week 300—9260.00 ± 8683.27
Week 306 (Follow-up)1237.01 ± 2856.882280.98 ± 7909.71

Adverse events

Collected over All Adverse Events (AEs) were collected from up to Week 24 in DB period and from end of Week 24 (Baseline of OLE Period) up to Week 306 in OLE Period regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Period - Adalimumab 40 mg0/184 (0%)13/184 (7.1%)62/184 (33.7%)
DB Period - Sarilumab 200 mg1/184 (0.5%)9/184 (4.9%)79/184 (42.9%)
OLE Period - Sarilumab 200 mg8/320 (2.5%)56/320 (17.5%)220/320 (68.8%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventDB Period - Adalimumab 40 mgDB Period - Sarilumab 200 mgOLE Period - Sarilumab 200 mg
PneumoniaInfections and infestations0/1840/1845/320
OsteoarthritisMusculoskeletal and connective tissue disorders1/1840/1845/320
CholelithiasisHepatobiliary disorders0/1840/1844/320
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/1840/1843/320
AnaemiaBlood and lymphatic system disorders0/1840/1842/320
CataractEye disorders0/1840/1842/320
Pancreatitis acuteGastrointestinal disorders0/1840/1842/320
Arthritis bacterialInfections and infestations1/1840/1840/320
Bursitis infectiveInfections and infestations0/1841/1840/320
MastitisInfections and infestations0/1841/1840/320
Most frequent other events
Showing 10 of 13
Most frequent other events
EventDB Period - Adalimumab 40 mgDB Period - Sarilumab 200 mgOLE Period - Sarilumab 200 mg
NasopharyngitisInfections and infestations14/18411/18460/320
NeutropeniaBlood and lymphatic system disorders1/18425/18459/320
BronchitisInfections and infestations7/18412/18441/320
Accidental overdoseInjury, poisoning and procedural complications11/1845/18439/320
Upper respiratory tract infectionInfections and infestations7/1843/18436/320
Urinary tract infectionInfections and infestations4/1845/18430/320
HypertensionVascular disorders3/1844/18428/320
Injection site erythemaGeneral disorders7/18414/18426/320
Alanine aminotransferase increasedInvestigations6/1847/18423/320
Back painMusculoskeletal and connective tissue disorders3/1843/18421/320

Baseline characteristics

Analysis was performed on randomized population that included all participants who received at least 1 dose or part of a dose of Investigational Medicinal Product (IMP).

Age, Continuous
Age, Continuous(years)Adalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mgTotal
Mean53.6 ± 11.950.9 ± 12.652.2 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mgTotal
Female150157307
Male352762
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Adalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mgTotal
Caucasian/White164171335
Black314
Asian/Oriental9211
Other91019
Disease Activity Score 28 based on erythrocyte sedimentation rate (DAS28-ESR)
Disease Activity Score 28 based on erythrocyte sedimentation rate (DAS28-ESR)(units on a scale)Adalimumab 40 mg/Sarilumab 200 mgSarilumab 200 mg/Sarilumab 200 mgTotal
Mean6.76 ± 0.836.83 ± 0.766.80 ± 0.80
08

Study locations

86 sites
  • Investigational Site Number 840407
    Covina, California 91723, United States
  • Investigational Site Number 840400
    Long Beach, California 90808, United States
  • Investigational Site Number 840141
    Whittier, California 90606, United States
  • Investigational Site Number 840130
    Lewes, Delaware 19958, United States
  • Investigational Site Number 840229
    Coral Gables, Florida 33134, United States
  • Investigational Site Number 840128
    Ormond Beach, Florida 32174, United States
  • Investigational Site Number 840403
    Saint Petersburg, Florida 33708, United States
  • Investigational Site Number 840140
    Tampa, Florida 33614, United States
  • Investigational Site Number 840073
    Cumberland, Maryland 21502, United States
  • Investigational Site Number 840202
    Hagerstown, Maryland 21740, United States
  • Investigational Site Number 840232
    Flint, Michigan 48504, United States
  • Investigational Site Number 840112
    Lincoln, Nebraska 68516, United States
  • Investigational Site Number 840402
    Charlotte, North Carolina 28210, United States
  • Investigational Site Number 840406
    Hickory, North Carolina 28601, United States
  • Investigational Site Number 840404
    Middleburg Heights, Ohio 44130, United States
  • Investigational Site Number 840127
    Oklahoma City, Oklahoma 73103, United States
  • Investigational Site Number 840074
    Mesquite, Texas 75150, United States
  • Investigational Site Number 152005
    Osorno, 5311092, Chile
  • Investigational Site Number 152001
    Puerto Varas, Chile
  • Investigational Site Number 152002
    Santiago, 7501126, Chile
  • Investigational Site Number 152050
    Santiago, 8207257, Chile
  • Investigational Site Number 152014
    Talca, Chile
  • Investigational Site Number 152015
    Temuco IX Region, 4790928, Chile
  • Investigational Site Number 152007
    Viña Del Mar, Chile
  • Investigational Site Number 203033
    Praha 11, 14800, Czechia
  • Investigational Site Number 203001
    Praha 2, 12850, Czechia
  • Investigational Site Number 203030
    Praha 4, Czechia
  • Investigational Site Number 203002
    Uherske Hradiste, 686 01, Czechia
  • Investigational Site Number 276058
    Köln, 50937, Germany
  • Investigational Site Number 276021
    Osnabrück, 49074, Germany
  • Investigational Site Number 348025
    Budapest, 1027, Hungary
  • Investigational Site Number 348020
    Budapest, 1033, Hungary
  • Investigational Site Number 348022
    Budapest, 1036, Hungary
  • Investigational Site Number 348024
    Szombathely, 9700, Hungary
  • Investigational Site Number 348023
    Veszprém, 8200, Hungary
  • Investigational Site Number 376032
    Ashkelon, 78278, Israel
  • Investigational Site Number 376031
    Haifa, 34362, Israel
  • Investigational Site Number 376030
    Ramat Gan, 52621, Israel
  • Investigational Site Number 376011
    Tel Aviv, 64239, Israel
  • Investigational Site Number 410005
    Daegu, 42601, Korea, Republic of
  • Investigational Site Number 410004
    Daejeon, 35233, Korea, Republic of
  • Investigational Site Number 410006
    Seoul, 01830, Korea, Republic of
  • Investigational Site Number 410001
    Seoul, 03080, Korea, Republic of
  • Investigational Site Number 604003
    Lima, LIMA 27, Peru
  • Investigational Site Number 604005
    Lima, LIMA 41, Peru
  • Investigational Site Number 604022
    Lima, Lima29, Peru
  • Investigational Site Number 616056
    Bytom, 41-902, Poland
  • Investigational Site Number 616015
    Elblag, Poland
  • Investigational Site Number 616005
    Lublin, 20-582, Poland
  • Investigational Site Number 616030
    Lublin, 20-954, Poland
  • Investigational Site Number 616055
    Nadarzyn, 05-830, Poland
  • Investigational Site Number 616018
    Poznan, 61-397, Poland
  • Investigational Site Number 616016
    Szczecin, 71-252, Poland
  • Investigational Site Number 616004
    Warszawa, 02-118, Poland
  • Investigational Site Number 616031
    Warszawa, 03-291, Poland
  • Investigational Site Number 642006
    Braila, 810019, Romania
  • Investigational Site Number 642010
    Bucharest, 011172, Romania
  • Investigational Site Number 642001
    Bucuresti, 010976, Romania
  • Investigational Site Number 642002
    Bucuresti, 020983, Romania
  • Investigational Site Number 642005
    Galati, 800578, Romania
  • Investigational Site Number 643006
    Kemerovo, 650000, Russian Federation
  • Investigational Site Number 643020
    Moscow, 115404, Russian Federation
  • Investigational Site Number 643001
    Moscow, 115522, Russian Federation
  • Investigational Site Number 643031
    Moscow, 121374, Russian Federation
  • Investigational Site Number 643030
    Moscow, 125284, Russian Federation
  • Investigational Site Number 643008
    Saint-Petersburg, 192242, Russian Federation
  • Investigational Site Number 643011
    Saratov, 410053, Russian Federation
  • Investigational Site Number 710011
    Cape Town, 7405, South Africa
  • Investigational Site Number 710007
    Cape Town, 7500, South Africa
  • Investigational Site Number 710004
    Kempton Park, 1619, South Africa
  • Investigational Site Number 724003
    Barakaldo, 48903, Spain
  • Investigational Site Number 724011
    Barcelona / Sabadell, 08208, Spain
  • Investigational Site Number 724015
    Barcelona, 08034, Spain
  • Investigational Site Number 724001
    Málaga, 29010, Spain
  • Investigational Site Number 724012
    Santiago De Compostela, 15705, Spain
  • Investigational Site Number 724007
    Sevilla, 41009, Spain
  • Investigational Site Number 804029
    Ivano-Frankivsk, 76018, Ukraine
  • Investigational Site Number 804048
    Kharkiv, 61058, Ukraine
  • Investigational Site Number 804014
    Kyiv, 01103, Ukraine
  • Investigational Site Number 804047
    Kyiv, 02125, Ukraine
  • Investigational Site Number 804037
    Lutsk, 43005, Ukraine
  • Investigational Site Number 804046
    Lviv, 79010, Ukraine
  • Investigational Site Number 804049
    Poltava, 36011, Ukraine
  • Investigational Site Number 804011
    Vinnitsya, 21018, Ukraine
  • Investigational Site Number 804043
    Vinnitsya, 21100, Ukraine
  • Investigational Site Number 826001
    Leytonstone, E11 1NR, United Kingdom
09

References and documents

Publications

  • Rubbert-Roth A, Furst DE, Fiore S, Praestgaard A, Bykerk V, Bingham CO, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. Arthritis Res Ther. 2022 Aug 25;24(1):207. doi: 10.1186/s13075-022-02891-x. PubMed 36008838 ↗
  • Rehberg M, Giegerich C, Praestgaard A, van Hoogstraten H, Iglesias-Rodriguez M, Curtis JR, Gottenberg JE, Schwarting A, Castaneda S, Rubbert-Roth A, Choy EHS; MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther. 2021 Dec;8(4):1661-1675. doi: 10.1007/s40744-021-00361-5. Epub 2021 Sep 14. Erratum In: Rheumatol Ther. 2021 Dec;8(4):1921-1922. doi: 10.1007/s40744-021-00389-7. PubMed 34519964 ↗
  • Strand V, Boklage SH, Kimura T, Joly F, Boyapati A, Msihid J. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab. Arthritis Res Ther. 2020 Oct 20;22(1):250. doi: 10.1186/s13075-020-02344-3. PubMed 33081825 ↗
  • Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GS, Gonzalez-Gay MA, Mandrup-Poulsen T, Fleischmann R. Interleukin-6 receptor blockade or TNFalpha inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020 Sep 9;22(1):206. doi: 10.1186/s13075-020-02229-5. PubMed 32907617 ↗
  • Genovese MC, Fleischmann R, Kivitz A, Lee EB, van Hoogstraten H, Kimura T, St John G, Mangan EK, Burmester GR. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Res Ther. 2020 Jun 10;22(1):139. doi: 10.1186/s13075-020-02194-z. PubMed 32522251 ↗
  • Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, Burmester GR, Lam G, Kimura T, Sadeh J, Weinreich DM, Yancopoulos GD, Graham NMH. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis Rheumatol. 2020 Sep;72(9):1456-1466. doi: 10.1002/art.41299. Epub 2020 Aug 25. PubMed 32343882 ↗
  • Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, van Hoogstraten H, Boklage SH, Sadeh J, Graham NMH, Boyapati A. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. Arthritis Res Ther. 2020 Apr 7;22(1):70. doi: 10.1186/s13075-020-02163-6. PubMed 32264972 ↗
  • Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gomez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open. 2019 Oct 18;5(2):e001017. doi: 10.1136/rmdopen-2019-001017. eCollection 2019. PubMed 31673415 ↗
  • Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. J Rheumatol. 2019 Oct;46(10):1259-1267. doi: 10.3899/jrheum.180904. Epub 2019 Mar 15. PubMed 30877216 ↗
  • Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017 May;76(5):840-847. doi: 10.1136/annrheumdis-2016-210310. Epub 2016 Nov 17. PubMed 27856432 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Jan 2016, 11 months.

Results were first posted in Jul 2017, 1 year 6 months after primary completion. A results delay was requested in Dec 2016.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 11 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2015
First posted
Jan 7, 2015
StartActual
Jan 28, 2015
Primary completionActual
Jan 20, 2016
CompletionActual
Dec 29, 2020
Results delay requested
Dec 7, 2016
Results first posted
Jul 25, 2017
Last update
Mar 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02332590
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 7, 2015
Start date
Jan 28, 2015
Primary completion
Jan 20, 2016
Completion
Dec 29, 2020
Results posted
Jul 25, 2017
Last update
Mar 28, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion